Moderna to Raise $2 Billion in Convertible Notes to Extend Cash Runway

Moderna (NASDAQ: MRNA) announced it is raising $2.0 billion through an offering of convertible notes, a move designed to extend its financial runway as it pivots from its COVID-19 vaccine success to new therapeutic areas.

The biotechnology company also has the option to issue an additional $300 million in notes, potentially bringing the total capital raised to $2.3 billion.

Bolstering the Balance Sheet

The capital raise is critical for Moderna, which held $1.72 billion in cash as of June 30, 2026. The company has been burning through approximately $600 million to $700 million per quarter, according to recent figures. This infusion is expected to extend its operational runway to between two and two-and-a-half years, providing crucial time to advance its pipeline.

Proceeds from the offering are earmarked for several key areas:

• Oncology Pipeline: Funding the development of its mRNA cancer vaccine, intismeran, which is being co-developed with Merck and recently produced positive Phase 3 data.
• Debt Repayment: Addressing existing financial obligations.
• Capped Call Transactions: The company will use a portion of the funds to enter into transactions designed to reduce potential shareholder dilution from the conversion of the notes into stock.

Navigating the Post-COVID Revenue Cliff

Ad

Moderna's need for capital is underscored by a dramatic decline in revenue following the peak of the pandemic. The company's revenue fell from $19.3 billion in fiscal 2022 to just $145 million in the second quarter of 2026 as demand for its COVID-19 vaccine evaporated.

While the notes are structured as zero-coupon, meaning Moderna will not make regular interest payments, the primary cost to shareholders is potential dilution. If the company's stock price rises significantly, noteholders can convert their debt into equity, increasing the total number of shares outstanding.

Outlook for Investors

This capital raise provides Moderna with a much-needed bridge to reach critical development milestones for its promising cancer vaccine. The extended runway could allow the company to get intismeran to a potential launch decision without needing to raise additional funds under less favorable conditions.

However, the high cash burn rate remains a significant concern for investors. The company's ability to manage costs and successfully commercialize new products will be essential to achieving long-term financial stability and justifying its valuation in a post-COVID market.